84176-62-5

Basic information

• Product Name: N-[3-allyl-4-hydroxyphenyl]acetamide
• Synonyms: N-[3-allyl-4-hydroxyphenyl]acetamide;N-[4-Hydroxy-3-(2-propenyl)phenyl]acetamide;Einecs 282-329-1
• CAS NO: 84176-62-5
• Molecular Formula: C₁₁H₁₃NO₂
• Molecular Weight: 191.22642
• EINECS: 282-329-1
• Mol File: 84176-62-5.mol
• Article Data: 4

Chemical Properties

• Boiling Point: 392.7°Cat760mmHg
• Flash Point: 191.3°C
• Appearance: /
• Density: 1.156g/cm³
• Vapor Pressure: 9.93E-07mmHg at 25°C
• Refractive Index: 1.596
• CAS DataBase Reference: N-[3-allyl-4-hydroxyphenyl]acetamide(CAS DataBase Reference)
• NIST Chemistry Reference: N-[3-allyl-4-hydroxyphenyl]acetamide(84176-62-5)
• EPA Substance Registry System: N-[3-allyl-4-hydroxyphenyl]acetamide(84176-62-5)

Safety Data

• Hazardous Substances Data: 84176-62-5(Hazardous Substances Data)

Usage

Synthesis Reference(s)

Journal of the American Chemical Society, 70, p. 1363, 1948 DOI: 10.1021/ja01184a023

InChI:InChI=1/C11H13NO2/c1-3-4-9-7-10(12-8(2)13)5-6-11(9)14/h3,5-7,14H,1,4H2,2H3,(H,12,13)

Upstream product

• 35736-25-5 3-(2-hydroxy-5-aminophenyl)-1-propene 
• 108-24-7 acetic anhydride 
• 6622-73-7 4-acetamidophenyl allyl ether 
• 121-69-7 N,N-dimethyl-aniline 
• 557-40-4 Allyl ether 
• 103-90-2 4-acetaminophenol 
• 106-95-6 allyl bromide 
• 1568-66-7 1-allyloxy-4-nitrobenzene 
• 100-02-7 4-nitro-phenol 
• 408507-62-0 2-Allyl-4-nitroso-phenol 
• 1688-69-3 p-allyloxyaniline 
• 111-90-0 ethoxyethoxyethanol 

Downstream Products

• 861295-49-0 N-(3-allyl-4-(allyloxy)phenyl)acetamide 
• 861295-67-2 N-(3,5-diallyl-4-hydroxy-phenyl)-acetamide 
• 1394965-64-0 C₂₆H₃₇NO₂ 
• 58546-89-7 1-benzofuran-5-amine 
• 152973-97-2 3-allyl-4-(3-[N-isopropylamino]-propoxy)acetanilide 
• 152974-06-6 3-allyl-4-(3-bromopropyloxy)-acetanilide 
• 119118-13-7 N-[2-(4-Chloro-phenylsulfanylmethyl)-2,3-dihydro-benzofuran-5-yl]-acetamide 
• 119118-11-5 N-(2-Phenylsulfanylmethyl-2,3-dihydro-benzofuran-5-yl)-acetamide 

Relevant articles and documents

CHEMICAL COMPOUNDS

The invention is directed to substituted salicylamide derivatives. Specifically, the invention is directed to compounds according to FormμLa (I): wherein R, R1,P, X, Y, and Z are as defined herein; or a pharmaceutically acceptable salt thereof. The compounds of the invention are inhibitors of CD73 and can be usefμL in the treatment of cancer, pre-cancerous syndromes and diseases associated with CD73 inhibition, such as AIDS, the treatment of HIV, autoimmune diseases, infections, atherosclerosis, and ischemia–reperfusion injury. Accordingly, the invention is further directed to pharmaceutical compositions comprising a compound of the invention. The invention is still further directed to methods of inhibiting CD73 activity and treatment of disorders associated therewith using a compound of the invention or a pharmaceutical composition comprising a compound of the invention.

Synthesis and SAR studies of 3-allyl-4-prenyloxyaniline amides as potent 15-lipoxygenase inhibitors

15-Lipoxygenases are one of the nonheme iron-containing proteins with ability of unsaturated lipid peroxidation in animals and plants. The critical role of the enzymes in formation of inflammations, sensitivities and some of cancers has been demonstrated in mammalians. Importance of the 15-lipoxygenases leads to development of mechanistic studies, products analysis and synthesis of their inhibitors. In this work new series of the 3-allyl-4-allyoxyaniline amides and 3-allyl-4-prenyloxyaniline amides were designed, synthesized and their inhibitory potency against soybean 15-lipoxygenase were determined. Among the synthetic amides, 3-allyl-4-(farnesyloxy)-adamantanilide showed the most potent inhibitory activity by IC50 value of 0.69 μM. SAR studies showed that in spite of prenyl length increases, the effects of the amide size and its electronic properties on the inhibitory potency became predominant. The SAR studies was also showed that the orientation of allyl and prenyloxy moieties toward Fe core of the SLO active site pocket is the most suitable location for enzyme inhibition.